JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Methylation Status and Expression of BRCA2 in Epithelial Ovarian Cancers in Indonesia
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Methylation Status and Expression of BRCA2 in Epithelial Ovarian Cancers in Indonesia
Pradjatmo, Heru;
  PDF(new window)
 Abstract
Ovarian cancer is the main cause of mortality in gynecological malignancy and extensive studies have been conducted to study the underlying molecular mechanisms. The BRCA2 gene is known to be an important tumor suppressor in ovarian cancer, thereby BRCA2 alterations may lead to cancer progression. However, the BRCA2 gene is rarely mutated, and loss of function is suspected to be mediated by epigenetic regulation. In this study we investigated the methylation status and gene expression of BRCA2 in ovarian cancer patients. Ovarian cancer pateints (n
 Keywords
BRCA2;epigenetic;methylation;epithelial ovarian cancer;survival;
 Language
English
 Cited by
1.
SET and MYND Domain-Containing Protein 3 (SMYD3) Polymorphism as a Risk Factor for Susceptibility and Poor Prognosis in Ovarian Cancer, Medical Science Monitor, 2016, 22, 1643-3750, 5131  crossref(new windwow)
2.
A novel loss-of-function heterozygous BRCA2 c.8946_8947delAG mutation found in a Chinese woman with family history of breast cancer, Journal of Cancer Research and Clinical Oncology, 2017, 143, 4, 631  crossref(new windwow)
 References
1.
An J, Wei Q, Liu Z et al (2010). Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis. Inter J of Mol Epid and Gen, 1, 1-10.

2.
Baldwin RL, Nemeth E, Tran H, et al (2000). BRCA1 promoter region hypermethylation in ovarian carcinoma: a populationbased study. Cancer Res, 60, 5329-33.

3.
Bosviel R, Michard E, Lavediaux G, et al (2011). Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls. Clinica Chimica acta. Inter J of Clin Chem, 412, 1472-5.

4.
Catteau A, Harris WH, Xu CF, Solomon E (1999). Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene, 18, 1957-65. crossref(new window)

5.
Chan KY, Ozcelik H, Cheung AN, Ngan HY, Khoo US (2002). Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res, 62, 4151- 56.

6.
Darehdori AS, Dastjerdi MN, Dahim H, et al (2012). Lack of significance of the BRCA2 promoter methylation status in Different Genotypes of the MTHFR a1298c polymorphism in ovarian cancer cases in Iran. Asian Pac J Cancer Prev, 13, 1833-6. crossref(new window)

7.
Dhillon VS, Shahid M, Husain SA (2004). CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer, 3, 1-8. crossref(new window)

8.
Gudmundsdottir K, Ashworth A (2006). The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene, 25, 5864-74. crossref(new window)

9.
Hedenfalk I, Duggan D, Chen Y, et al (2001). Gene-expression profiles in hereditary breast cancer. The New Eng J of Med, 344, 539-48. crossref(new window)

10.
Herman JG, Baylin SB, (2003). Gene silencing in cancer in association with promoter hypermethylation. The New Engl J of Medicine, 349, 2042-54. crossref(new window)

11.
Hilton JL, Geisler JP, Rathe JA, et al (2002). Inactivation of BRCA1 and BRCA2 in Ovarian Cancer. J Natl Cancer Inst, 94, 1396-406. crossref(new window)

12.
Holschneider CH, Berek JS (2000). Ovarian cancer: epidemiology, biology, and prognostic factors. Seminars in Surgical Oncology, 19, 3-10. crossref(new window)

13.
Jones PA (1996). DNA methylation errors and cancer. Cancer Res, 56, 2463-7.

14.
Kontorovich T, Cohen Y, Nir U, Friedman E (2009). Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. Breast Cancer Res Treat, 116, 195-200. crossref(new window)

15.
Korstanje R, Albers JJ, Wolfbauer G, et al (2004). Quantitative trait locus mapping of genes that regulate phospholipid transfer activity in SM/J and NZB/BlNJ inbred mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 155-60. crossref(new window)

16.
Laird PW (2003). The power and the promise of DNA methylation markers. Nat Rev Cancer, 3, 253-66. crossref(new window)

17.
Lesnock JL, Darcy KM, Tian C, et al (2013). BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. British J Cancer, 108, 1231-7. crossref(new window)

18.
Li SD, Zhang JR,Wang YQ,Wan XP 2010. The role of microRNAs in ovarian cancer initiation and progression. J Cell Mol Med, 14, 2240-49. crossref(new window)

19.
McCabe N, Turner NC, Lord CJ, et al (2006). Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res, 66, 8109-15. crossref(new window)

20.
Meetei AR, Levitus M, Xue Y, et al (2004). X-linked inheritance of Fanconi anemia complementation group B. Nature Genetics, 36, 1219-24. crossref(new window)

21.
Olek A, Oswald J, Walter J (1996). A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res, 24, 5064-6. crossref(new window)

22.
Pradjatmo H, Dasuki D, Anwar M, Mubarika S, Harijadi (2014). Methylation status and immunohistochemistry of BRCA1 in epithelial ovarian cancer. Asian Pac J Cancer Prev, 15, 9479-85. crossref(new window)

23.
Rathi A, Virmani AK, Schorge JO, et al (2002). Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res, 8, 3324-31.

24.
Shabanizadeh A, Dahim H, Salahshoor R, et al (2013). Promoter methylation status and protein expression of BRCA2 in patients with epithelial ovarian cancer. Middle East Journal of Cancer, 4, 15-20.

25.
Thrall M, Gallion HH, Kryscio R, et al (2006). BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Inter J of Gynecol Cancer, 16, 166-71. crossref(new window)

26.
Venkitaraman AR (2002). Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell, 108, 171-82. crossref(new window)

27.
Yanagawa N, Tamura G, Honda T, et al (2004). Demethylation of the synuclein gamma gene CpG island in primary gastric cancers and gastric cancer cell lines. Clin Cancer Res, 10, 2447-51. crossref(new window)